Angiomyolipoma medical therapy: Difference between revisions
No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
There is no treatment for [[angiomyolipoma]]; the mainstay of therapy is embolisation or resection. | |||
==Treatment== | ==Treatment== | ||
Revision as of 19:17, 22 September 2015
|
Angiomyolipoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Angiomyolipoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Angiomyolipoma medical therapy |
|
Risk calculators and risk factors for Angiomyolipoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
There is no treatment for angiomyolipoma; the mainstay of therapy is embolisation or resection.
Treatment
Angiomyolipomas found incidentally usually require no therapy
Patients with kidney loss should be monitored for hypertension (and treated for it if discovered) and avoid nephrotoxic drugs such as certain pain relievers and IV contrast agents. Such patients who are unable to communicate effectively (due to age or intellectual disability) are at risk of dehydration. Where multiple or large angiomyolipomas have caused chronic kidney disease, dialysis is required.[1]
Rapamycin and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when TSC1 and TSC2 genes are broken. Small studies showed the lesions shrank but that the drugs were often toxic. The use of these drugs remains at the research stage.[1]